QIAGEN N.V.

QGEN Healthcare Diagnostics & Research

QIAGEN N.V.’s revenue for fiscal 2025 (year ended December 2025) was $2.1 billion, up 5.65% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 7.94%, free cash flow grew 30.5% and total debt rose 13.8%, each against the same quarter a year earlier.

46.13 0.04 −0.09%
Market cap
$9.5B
P/E
23.6×
Fwd P/E
17.5×
Dividend yield
0.76%
F-score
8/9
Altman Z
3.81
Beneish M
−2.60
Dividend safety
66/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

23.07 22.30 20.91 20.03
P/S ratio
4.45 4.67 3.95 3.84
P/FCF ratio
19.48 21.84 20.52 18.31
P/Operating CF
55.78 51.92 82.37 40.20
P/B ratio
2.52 2.59 2.49 2.40
EV/Sales
4.66 5.18 4.66 4.25
EV/EBITDA
14.16 16.33 15.31 13.70
EV/FCF
20.41 24.20 24.24 20.24
Current Ratio
2.60 3.90 3.21 2.85
Net Debt/EBITDA
2.41 3.71 7.34 4.63
Debt/Equity
0.58 0.44 0.49 0.49
Earnings Yield
4.34% 4.48% 4.78% 4.99%
Free Cash Flow Yield
5.13% 4.58% 4.87% 5.46%
Free Cash Flow per Share
0.56 0.54 0.25 0.76
Book value per Share
17.71 17.39 16.09 16.27
Free Cash Flow
114.57 116.55 52.15 157.32
EV/EBIT
19.86 23.23 22.51 20.02
Other line items

Show all line items

Columns are period end dates